NovaBridge Biosciences (NBP) Stock

NovaBridge Biosciences (NBP) is a Healthcare stock trading at $1.48 (as of 2026-06-18), with a market capitalization of $488.30M and a trailing P/E of -7.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

NovaBridge Biosciences develops immuno-oncology therapeutics for cancer, including bispecific and monoclonal antibody candidates such as givastomig, ragistomig, and uliledlimab, as well as FE301 under a licensing arrangement. Its programs are focused on clinical development in the United States and are conducted with partners including Bristol Myers Squibb, ABL Bio, TJ Bio, and Ferring International Center SA.

Valuation — source: SEC EDGAR (first-party)
Price	$1.48
Market Cap	$488.30M
P/E Ratio	-7.5
EV / EBITDA	-2.2
Price / Book	1.80
Price / Sales	54.74

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$7.61M
Net Margin	-607.9%
Return on Equity	-20.0%
Current Ratio	8.09
Revenue Growth (YoY)	1.7%
EPS Growth (YoY)	75.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	0.52 (distress)

Valuation vs Sector & Industry
Stock P/E	-7.5
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-135.7%
vs Industry	-143.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	JANUS HENDERSON GROUP PLC ($14.81M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Xi-Yong Fu
Employees	32
Country	US
IPO Date	2020-01-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.